Clinical Trial Update: Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nilotinib in combination with pegylated interferon alpha-2a for untreated chronic phase chronic myeloid leukemia has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)
• Pegylated Interferon Alpha-2a (pegylated interferon alfa-2a)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED